Psilocybin: a psychedelic alternative to antidepressants?
Pharmaceutical journal/The pharmaceutical journal January 1, 2022 DOI: 10.1211/pj.2022.1.169269 via OpenAlex
Summary
AI-generated from the abstractIn the largest trial of the psychedelic drug psilocybin to date, a single 25mg dose combined with psychological support improved symptoms of treatment-resistant depression for up to 12 weeks. Previous work had suggested an antidepressant mechanism for psilocybin therapy and shown it is at least as effective as other treatments.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg |
| Duration | 12-week follow-up |
| Topics | Psilocybin |
| Keywords | Hallucinogen Medicine Psychiatry Psychology |
| Key finding | A single 25mg dose of psilocybin with psychological support improved symptoms of treatment-resistant depression for up to 12 weeks. |
Abstract
In November 2022, the largest trial to date of the psychedelic drug, psilocybin, showed that — alongside psychological support — a single 25mg dose could improve the symptoms of treatment-resistant depression for up to 12 weeks. Previous studies have suggested an antidepressant mechanism for psilocybin therapy and have shown that psilocybin is at least as […]